IC
FLNA

Ikarian Capital’s Filana Therapeutics FLNA Stock Holding History

Ikarian Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,362
Closed -$458K – 253
2021
Q2 		$458K Buy
+5,362
New +$287K 0.04% 192
2020
Q2 		– Sell
-300,000
Closed -$1.23M – 206
2020
Q1 		$1.23M Buy
+300,000
New +$1.99M 0.09% 114

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ikarian Capital's FLNA Position: Q3 2021 in Review

Ikarian Capital sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 5,362 shares — an estimated $458K sold.

Ikarian Capital first reported a position in FLNA in Q1 2020 and held it in 2 quarters. The position peaked at $1.23M in Q1 2020. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

  • Ikarian Capital reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ikarian Capital sold 5,362 Filana Therapeutics shares in Q3 2021, an estimated $458K.
  • Ikarian Capital first reported a position in Filana Therapeutics in Q1 2020 and held it in 2 quarters.
  • Ikarian Capital's Filana Therapeutics position peaked at $1.23M in Q1 2020.
  • 180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.